- Home
- BITF vs HROW Comparison
BITF vs HROW Comparison
Compare BITF & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BITF
- HROW
- Stock Information
- Founded
- BITF 2017
- HROW 1998
- Country
- BITF Canada
- HROW United States
- Employees
- BITF N/A
- HROW N/A
- Industry
- BITF Finance: Consumer Services
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- BITF Finance
- HROW Health Care
- Exchange
- BITF Nasdaq
- HROW Nasdaq
- Market Cap
- BITF 1.7B
- HROW 1.4B
- IPO Year
- BITF N/A
- HROW N/A
- Fundamental
- Price
- BITF $4.54
- HROW $38.68
- Analyst Decision
- BITF Strong Buy
- HROW Strong Buy
- Analyst Count
- BITF 3
- HROW 7
- Target Price
- BITF $3.83
- HROW $68.50
- AVG Volume (30 Days)
- BITF 124.4M
- HROW 848.3K
- Earning Date
- BITF 11-12-2025
- HROW 11-12-2025
- Dividend Yield
- BITF N/A
- HROW N/A
- EPS Growth
- BITF N/A
- HROW N/A
- EPS
- BITF N/A
- HROW N/A
- Revenue
- BITF $245,664,000.00
- HROW $227,661,000.00
- Revenue This Year
- BITF $62.42
- HROW $43.92
- Revenue Next Year
- BITF $11.07
- HROW $41.32
- P/E Ratio
- BITF N/A
- HROW N/A
- Revenue Growth
- BITF 42.25
- HROW 47.69
- 52 Week Low
- BITF $0.67
- HROW $20.85
- 52 Week High
- BITF $6.60
- HROW $55.75
- Technical
- Relative Strength Index (RSI)
- BITF 57.59
- HROW 43.27
- Support Level
- BITF $3.70
- HROW $38.32
- Resistance Level
- BITF $5.41
- HROW $42.31
- Average True Range (ATR)
- BITF 0.68
- HROW 2.44
- MACD
- BITF -0.13
- HROW -0.36
- Stochastic Oscillator
- BITF 38.64
- HROW 32.87
About BITF Bitfarms Ltd.
Bitfarms Ltd engaged in the cryptocurrency Mining industry mainly consists of selling its computational power used for hashing calculations for cryptocurrency mining in multiple jurisdictions. Its geographic operations are currently located in Canada, the United States, Argentina. It owns and operates server farms comprised of computers designed to validate transactions on the Bitcoin Blockchain.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.